Geoffroy M, Lemesle M, Kleinclauss A, Mazerbourg S, Batista L, Barberi-Heyob M, Bastogne T, Boireau W, Rouleau A, Dupommier D, Boisbrun M, Comoy C, Flament S, Grillier-Vuissoz I, Kuntz S

Int J Mol Sci. 2022 06 20;23(12):

New desulfured troglitazone derivatives: Improved synthesis and biological evaluation.

Dupommier D, Muller C, Comoy C, Mazerbourg S, Bordessa A, Piquard E, Pawlak M, Piquard F, Martin H, De Fays E, Grandemange S, Flament S, Boisbrun M

Eur J Med Chem. 2019 Dec 4;187:111939

Protein N-glycosylation alteration and glycolysis inhibition both contribute to the antiproliferative action of 2-deoxyglucose in breast cancer cells.

Berthe A, Zaffino M, Muller C, Foulquier F, Houdou M, Schulz C, Bost F, De Fay E, Mazerbourg S, Flament S

Breast Cancer Res. Treat.. 2018 Jul 3;:

Insulin-Like Growth Factor Binding Proteins and IGFBP Proteases: A Dynamic System Regulating the Ovarian Folliculogenesis.

Mazerbourg S, Monget P

Front Endocrinol (Lausanne). 2018 ;9:134

Δ2-Troglitazone promotes cytostatic rather than pro-apoptotic effects in breast cancer cells cultured in high serum conditions.

Berthe A, Flament S, Grandemange S, Zaffino M, Boisbrun M, Mazerbourg S

Cell Cycle. 2016 Dec;15(24):3402-3412

Reprofiling of Troglitazone Towards More Active and Less Toxic Derivatives: A New Hope for Cancer Treatment?

Mazerbourg S, Kuntz S, Grillier-Vuissoz I, Berthe A, Geoffroy M, Flament S, Bordessa A, Boisbrun M

Curr Top Med Chem. 2016 ;16(19):2115-24

PPARgamma-inactive Delta2-troglitazone independently triggers ER stress and apoptosis in breast cancer cells.

Colin-Cassin C, Yao X, Cerella C, Chbicheb S, Kuntz S, Mazerbourg S, Boisbrun M, Chapleur Y, Diederich M, Flament S, Grillier-Vuissoz I

Mol Carcinog. 2015 May;54(5):393-404

Energy restriction mimetic agents to target cancer cells: comparison between 2-deoxyglucose and thiazolidinediones.

Kuntz S, Mazerbourg S, Boisbrun M, Cerella C, Diederich M, Grillier-Vuissoz I, Flament S

Biochem Pharmacol. 2014 Nov 1;92(1):102-11

Optimization of troglitazone derivatives as potent anti-proliferative agents: towards more active and less toxic compounds.

Bordessa A, Colin-Cassin C, Grillier-Vuissoz I, Kuntz S, Mazerbourg S, Husson G, Vo M, Flament S, Martin H, Chapleur Y, Boisbrun M

Eur J Med Chem. 2014 Aug 18;83:129-40

Synthesis of new troglitazone derivatives: anti-proliferative activity in breast cancer cell lines and preliminary toxicological study.

Salamone S, Colin C, Grillier-Vuissoz I, Kuntz S, Mazerbourg S, Flament S, Martin H, Richert L, Chapleur Y, Boisbrun M

Eur J Med Chem. 2012 May;51:206-15

EGR1 expression: a calcium and ERK1/2 mediated PPARgamma-independent event involved in the antiproliferative effect of 15-deoxy-Delta12,14-prostaglandin J2 and thiazolidinediones in breast cancer cells.

Chbicheb S, Yao X, Rodeau JL, Salamone S, Boisbrun M, Thiel G, Spohn D, Grillier-Vuissoz I, Chapleur Y, Flament S, Mazerbourg S

Biochem Pharmacol. 2011 May 1;81(9):1087-97

Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines.

Lecomte J, Flament S, Salamone S, Boisbrun M, Mazerbourg S, Chapleur Y, Grillier-Vuissoz I

Breast Cancer Res Treat. 2008 Dec;112(3):437-51

Use of combined in silico expression data and phylogenetic analysis to identify new oocyte genes encoding RNA binding proteins in the mouse.

Drouilhet L, Paillisson A, Bontoux M, Jeanpierre E, Mazerbourg S, Monget P

Mol Reprod Dev. 2008 Dec;75(12):1691-700.

Female-enriched expression of ERalpha during gonad differentiation of the urodele amphibian Pleurodeles waltl.

Ko CI, Chesnel A, Mazerbourg S, Kuntz S, Flament S, Chardard D

Gen Comp Endocrinol. 2008 Apr 1;156(2):234-45

Genomic analyses facilitate identification of receptors and signalling pathways for growth differentiation factor 9 and related orphan bone morphogenetic protein/growth differentiation factor ligands.

Mazerbourg S, Hsueh AJ

Hum Reprod Update. 2006 Jul-Aug;12(4):373-83

Adenoviral gene transfer allows Smad-responsive gene promoter analyses and delineation of type I receptor usage of transforming growth factor-beta family ligands in cultured human granulosa luteal cells.

Kaivo-Oja N, Mottershead DG, Mazerbourg S, Myllymaa S, Duprat S, Gilchrist RB, Groome NP, Hsueh AJ, Ritvos O

J Clin Endocrinol Metab. 2005 Jan;90(1):271-8